Memantine Grindeks (Memantine Hydrochloride)

Memantine acts on glutamatergic pathways that contribute to neurodegeneration, primarily in Alzheimer’s disease.

• Alzheimer’s disease (mild to moderate): modest improvement in cognition and daily functioning.
• Alzheimer’s disease (moderate to severe): helps maintain functional abilities and may slow symptom progression.
• Alzheimer’s disease with behavioral symptoms: may reduce agitation and aggression associated with the condition.

• Memantine Hydrochloride binds to the NMDA (N‑methyl‑D‑aspartate) receptor at a site distinct from the glutamate binding site, acting as a non‑competitive antagonist. By blocking excessive calcium influx through the receptor channel, it reduces excitotoxic neuronal injury while preserving normal synaptic transmission, thereby mitigating progressive neurodegeneration associated with Alzheimer’s disease.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness: mild to moderate vertigo or light‑headedness.
• Headache: transient cranial pain.
• Constipation: reduced bowel movements.
• Confusion: occasional disorientation.
• Fatigue: feeling unusually tired.
• Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring immediate medical attention.
• Cardiac arrhythmia: irregular heart rhythm.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: signs of liver injury.
• Suicidal ideation: thoughts of self‑harm.
• Neuroleptic malignant‑like syndrome: high fever, muscle rigidity, autonomic instability.

When prescribing memantine, clinicians should consider several safety factors.

• Renal impairment: dose adjustment may be required.
• Hepatic impairment: use with caution and monitor liver function.
• History of seizures: monitor for increased seizure activity.
• Concomitant NMDA antagonists: avoid additive neurotoxicity.
• Pregnancy: risk unknown; avoid unless clearly needed.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Amantadine: increased neurotoxic risk.
• Other NMDA antagonists: additive central nervous system depression.
• Strong CYP3A4 inducers (e.g., rifampin): may reduce memantine exposure.

Moderate Interactions (Monitor Closely)

• Antihypertensives: potential enhancement of hypotensive effect.
• Anticholinergics: may worsen cognitive symptoms.
• Diuretics: increased risk of dizziness and electrolyte imbalance.
• Proton pump inhibitors: possible alteration of absorption.
• SSRIs: monitor for serotonin syndrome signs.